Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Afraxis, PsychoGenics alliance to offer ESP drug discovery technology
The technology can evaluate as many as 250,000 dendritic spines per month as well as simultaneously assess spine quantity and morphology in multiple brain regions. The ESP can
The technology can evaluate as many as 250,000 dendritic spines per month as well as simultaneously assess spine quantity and morphology in multiple brain regions. The ESP can
Advate is a full-length recombinant factor VIII (FVIII) product, used to control and prevent bleeding episodes in patients with hemophilia A. Baxter’s BioScience business clinical affairs vice president
Qsymia will be used to manage chronic weight in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight)
The new CPU with 96 beds for overnight stays, will conduct early-phase clinical pharmacology studies in normal healthy volunteers, special populations and patient populations over a spectrum of
The pre existing agreement between the two companies in Europe, which involves the OneKey Healthcare Prescriber (HCP) database, brick structure definitions, local data and data integration projects, will
Dynamic monitoring feature allows pharmaceutical organizations, who conduct clinical trials, to reduce monitoring costs. The new feature also allows customers to control how much of the data in
The terms of the transaction include aggregate potential milestone payments of up to $3.6m and royalties ranging from low double digit to high single digit royalties on commercial
According to the agreement, PCT will complete a technology transfer of SOTIO’s current product manufacturing and analytical procedures into PCT’s ongoing CDMO operations. PCT will subsequently implement and
The Phase I dose-escalation trial will enrol up to 18 patients with bavituximab in combination with the chemotherapeutic agent capecitabine and radiation therapy. The study principal investigator, the
BodyGuard includes beta glucan, astragalus, Echinacea purpura, green tea extract and olive leaf extract. VitalMax relates that its new product contains an arsenal of powerful immune-system boosters that